Antipsychotic Polypharmacy and Metabolic Disorder Risk in Individuals With Schizophrenia
What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?
Source: psychiatrictimes.com